Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Liquidia Corporation to Participate in Upcoming Investor Conferences

Liquidia Corporation has announced its participation in two upcoming investor conferences, highlighting its commitment to advancing therapies for respiratory and vascular diseases. The 2026 Raymond James Biotech Innovation Symposium on April 14 will feature one-on-one meetings with key executives, including COO Michael Kaseta and CBO Jason Adair. Following that, the 25th Annual Needham Virtual Healthcare Conference on April 15 will include a fireside chat with CEO Dr. Roger Jeffs and Kaseta, where they will provide insights into the company’s business strategies and developments.

These conferences come at a pivotal time as Liquidia continues to leverage its proprietary PRINT® Technology to innovate in the treatment of pulmonary arterial hypertension (PAH) and related conditions. The company’s flagship product, YUTREPIA® (treprostinil) inhalation powder, exemplifies this approach, offering a novel delivery method for patients. Additionally, Liquidia is advancing its pipeline with L606, an investigational extended-release formulation of treprostinil designed for twice-daily administration, indicating a strategic focus on improving patient adherence and outcomes through enhanced drug delivery systems.

The implications of Liquidia’s advancements extend beyond immediate product offerings. By refining delivery mechanisms and exploring new formulations, the company is positioning itself to significantly impact treatment paradigms in pulmonary diseases. This could accelerate the timeline for bringing innovative therapies to market, ultimately enhancing the therapeutic landscape for patients suffering from chronic respiratory conditions. As Liquidia continues to engage with investors and stakeholders, its developments may also influence funding and collaborative opportunities within the broader biotech ecosystem, particularly in the realm of targeted therapies for complex diseases.

Source: globenewswire.com